Skip to content

Impact of Muscle and Tendon Dysfunction in People With Type 2 Diabetes Mellitus

Impact of Muscle and Tendon Dysfunction on the Mechanics of Muscle Contraction and Locomotion Capacity in People With Type 2 Diabetes Mellitus, and Efficacy of a Passive Stretching Training Program to Counteract These Alterations

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05585502
Acronym
T2D_MTU
Enrollment
46
Registered
2022-10-18
Start date
2022-12-10
Completion date
2024-04-30
Last updated
2026-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Keywords

Type 2 Diabetes Mellitus, Muscle and tendon disorders, locomotion capacity, passive stretching

Brief summary

Diabetes is a chronic-degenerative metabolic disorder that has reached pandemic proportions mainly because of the increasing incidence and prevalence of type 2 diabetes mellitus (T2D). Diabetes hurts cardiovascular function due to chronic hyperinsulinemia and hyperglycemia, along with increased advanced glycation end products (AGEs) causing nonenzymatic glycation of soft tissues, including muscle and tendon, and leading to an increase in muscle and tendon stiffness. In turn, the stiffening of the muscle-tendon complex reduces its capability to change in shape, affecting its potential for modulating the mechanical request during contraction (and locomotion), also increasing the metabolic demands during walking. The present, multi-disciplinary, project combines several experimental methods and procedures to investigate the impact of muscle and tendon alterations on the mechanics of muscle contraction and locomotion capacity in T2D patients. In this project, we also propose a new training approach (minute oscillation stretching) to counteract these possible alterations (e.g. to decrease muscle and tendon stiffness).

Detailed description

Diabetes is a chronic-degenerative metabolic disorder that has reached pandemic proportions, mainly because of the increasing incidence and prevalence of type 2 diabetes mellitus (T2D). According to the International Diabetes Federation (IDF, 2017), 425 million people suffer from diabetes worldwide and these may rise to 629 million in 2045 . Within this epidemiological perspective, diabetes emerges as one of the main metabolic disorders with substantial costs for regional and national sanitary systems. Diabetes hurts cardiovascular function due to chronic hyperinsulinemia and hyperglycemia, along with increased advanced glycation end products (AGEs), pro-inflammatory cytokines, oxidative stress, obesity, dyslipidemia, and physical inactivity, all of which contribute to vascular dysfunction. In particular, several studies have shown that AGEs exert their negative effects through binding to a specific cellular receptor (RAGE), found in several cell systems such as monocytes and endothelial cells. However, little attention has been paid, so far, to alterations in the musculoskeletal system, which may contribute to the decline of the general state of health of diabetic people and may limit the therapeutic use of exercise in these subjects. Diabetes causes non-enzymatic glycation of soft tissues, including muscle and tendon, leading to an increase in muscle and tendon stiffness. It was observed that Achilles tendon stiffness and skin connective tissue cross-linking are greater in diabetic patients compared to controls and it has been suggested that the elevated tendon stiffness may influence gait parameters. Indeed, during walking, diabetic patients display less Achilles tendon elongation, higher tendon stiffness and higher tendon hysteresis compared to healthy controls. The higher energy cost of walking in diabetic patients could thus be related to an impairment of the Achilles tendon function. The stiffening of the muscle, on the other hand, reduces its capability to change in shape, affecting its potential for modulating the mechanical request during contraction (and locomotion), also increasing the metabolic demands. Therefore, investigating the mechanical alterations caused by an increase in muscle and tendon stiffness could provide new insights into diabetes pathophysiology. Training strategies able to reduce muscle and tendon stiffness are expected to improve muscle-tendon function and locomotor capability of diabetic patients. Even if strength and endurance training protocols allow to improve both blood glucose and muscle contractile function, they seem ineffective in reducing muscle and tendon stiffness in T2D patients. Notably, these training modalities present a significant dropout in the diabetic population, generally higher than 25%. Static and dynamic stretching are effective in decreasing muscle and tendon stiffness but, in both cases, the decrease in stiffness is associated with a temporary decrease in muscle and tendon mechanical function. Recently, a new stretching modality (minute oscillation stretching, MOS) was proposed that allows to condition the plantar-flexors muscle-tendon units by providing repetitive small longitudinal length changes using a passive stretch of the ankle joint. In young and healthy participants, a single session of unilateral MOS was sufficient to reduce muscle and tendon stiffness without affecting the muscle strength of the tested leg. Since the plantar-flexor muscles are the most important propulsive muscles for human locomotion, it can be expected that MOS training for the plantar-flexor may improve locomotor capability in diabetic people too. It is noteworthy that, due to the current SARS-Covid-19 pandemic, this training modality can be easily performed at home, under telemedicine training supervision, since no specific equipment is needed. To summarize, a better understanding of the altered muscle and tendon mechanical properties in TD2 patients and of the effects that these alterations have on muscle contraction and locomotion capability can help in furthering our understanding on how diabetes affects physical activity, leading to inactivity. Finally, to investigate if and how these alterations could be reduced using a simple training program (MOS training), can help in designing more effective interventions, allowing to prescribe training modalities that these patients can easily perform (possibly limiting dropout).

Interventions

OTHERTraining (minute oscillation stretching)

The training session involves the use of an elastic band that the subjects will use to induce passive ankle flexion /extensions (with a frequency of 1 Hz): 10 repetitions will be performed with 60 s exercise and 30 s of pause in-between. At the end of the session, the subjects will fill a diary with data of perceived intensity of exercise and localized ankle pain. The telemedicine session will be conducted by trained personnel.

Sponsors

Universita di Verona
Lead SponsorOTHER
Azienda Ospedaliera Universitaria Integrata Verona
CollaboratorOTHER
University of Padova
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

The first part of the project is a cross-sectional design to test the association between: diabetic condition -\> increase in muscle and tendon stiffness -\> impairment of muscle-tendon function -\> increase in the energy expenditure of locomotion (walking). The second part of the project is an intervention study that aims to test the effects of a stretching training program on muscle and tendon stiffness, muscle function and locomotor (walking) capacity.

Eligibility

Sex/Gender
ALL
Age
50 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* body mass index between 23 and 30 kg/m2 * moderate level of physical activity in the everyday life (assessed by means of the International Physical Activity Questionnaires, IPAQ)

Exclusion criteria

* neuropathy of nondiabetic origin * severe neuropathy * foot ulcers * arterial insufficiency * arthritis of the ankle/foot * previous foot/knee surgery * previous Achille tendon rupture * previous Charcot foot * cardiovascular and respiratory deficits that would impede the performance of the locomotion test * insulin therapy

Design outcomes

Primary

MeasureTime frameDescription
Tendon Stiffness Differences Between T2D Patients and ControlsData were collected at baseline (pre-intervention)Achilles tendon stiffness (units: Nm/mm) was evaluated during isometric maximum voluntary contractions. In turn, stiffness was calculated based on the ratio between Torque values (units: Nm), which were recorded using a dynamometer (Cybex Norm), and tendon elongation values (units: mm), which were recorded using an ultrasound scanner (MycrusExt, Telemed).

Secondary

MeasureTime frameDescription
Effect of Training on Tendon Stiffness (in Patients)Data were collected at baseline and immediately after the intervention (10 weeks of training).Achilles tendon stiffness (units: Nm/mm) were calculated as described in outcome 1 in diabetic patients. Changes in these variables were calculated between baseline and post training.
Tissue Glycation Indicators (Hb1Ac) in T2D Patients and ControlsData were collected at baseline (pre-intervention)Glycated hemoglobin was assessed in blood samples as a measure of long-term glycation.
Tissue Glycation Indicators (RAGE) in T2D Patients and ControlsData were collected at baseline (pre-intervention)RAGE were assessed in skin biopsies as a measure of long-term glycation.

Countries

Italy

Contacts

PRINCIPAL_INVESTIGATORPaola Zamparo, PhD

Universita di Verona

Baseline characteristics

Characteristic
Age, Continuous62.5 years
STANDARD_DEVIATION 4.5
BMI (body mass index)25.6 kg/m2
STANDARD_DEVIATION 2.8
IPAQ (levels of physical activity)1597 MET-min/week
STANDARD_DEVIATION 571
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
Italy
46 participants
Sex: Female, Male
Female
9 Participants
Sex: Female, Male
Male
8 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 280 / 18
other
Total, other adverse events
0 / 280 / 18
serious
Total, serious adverse events
0 / 280 / 18

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 7, 2026